New hope for tough cancers: experimental drug targets key mutation
NCT ID NCT07435038
Summary
This study is testing a new oral drug called BPI-572270 for people with advanced cancers that have specific RAS genetic mutations. Researchers want to find the safest and most effective dose, and see if it helps control cancers like lung, colorectal, and pancreatic cancer that have stopped responding to standard treatments. The trial will enroll about 120 adults who have already tried appropriate standard therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.